Clinical Trials Logo

Sintilimab clinical trials

View clinical trials related to Sintilimab.

Filter by:
  • Active, not recruiting  
  • Page 1

NCT ID: NCT06342167 Active, not recruiting - Radiotherapy Clinical Trials

Efficacy and Safety of Concurrent PD-1 Inhibitor and Radiotherapy With Immunonutrition for Esophageal Squamous Cell Carcinoma

Start date: March 14, 2024
Phase: Phase 2
Study type: Interventional

At present, concurrent chemoradiotherapy (cCRT) with platin-based dual-drug regimen is the standard treatment for inoperable, locally advanced esophageal cancer in patients with a good performance status. However, cCRT has substantial toxic effects, and a large number of patients with older age, malnutrition and other morbidities, cannot tolerate cCRT. Several phase II trials showed combining PD-1 inhibitor with definitive cCRT provided encouraging activity and acceptable toxicity in patients with locally advanced esophageal squamous cell carcinoma (LA-ESCC). Therefore, this single-arm, multicenter, phase II trial aims to assess the efficacy and safety of immunotherapy plus radiotherapy with immunonutrition support in patients with LA-ESCC and positive PD-L1 expression who are intolerant to cCRT.

NCT ID: NCT05400070 Active, not recruiting - Lung Cancer Clinical Trials

Neoadjuvant PD-1 Inhibitor (Sintilimab), Anlotinib Combined With Chemotherapy in Resectable Stage IIA-IIIB NSCLC

Start date: March 1, 2021
Phase: Phase 2
Study type: Interventional

primary purposeļ¼šObserve the pathological complete response rate (PCR) of postoperative tumor tissue resection and evaluate the safety of the treatment process.